ScoreWhy is Senores Pharmaceuticals Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.94 times
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 2.94 times
- The company has been able to generate a Return on Capital Employed (avg) of 8.61% signifying low profitability per unit of total capital (equity and debt)
2
Healthy long term growth as Net Sales has grown by an annual rate of 85.60% and Operating profit at 130.72%
3
With a growth in Net Profit of 138.15%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 2 consecutive quarters
- PBT LESS OI(Q) At Rs 35.23 cr has Grown at 129.2% (vs previous 4Q average)
- NET SALES(Q) At Rs 161.76 cr has Grown at 41.9% (vs previous 4Q average)
- OPERATING PROFIT TO INTEREST(Q) Highest at 8.00 times
4
With ROE of 7.2, it has a Very Expensive valuation with a 4.4 Price to Book Value
- Over the past year, while the stock has generated a return of 0.00%, its profits have risen by 86%
5
Majority shareholders : Promoters
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Senores Pharma. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
85.60%
EBIT Growth (5y)
130.72%
EBIT to Interest (avg)
3.36
Debt to EBITDA (avg)
4.13
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
0.40
Tax Ratio
17.33%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.89%
ROCE (avg)
8.59%
ROE (avg)
11.42%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
61
Industry P/E
34
Price to Book Value
4.40
EV to EBIT
49.67
EV to EBITDA
40.34
EV to Capital Employed
4.24
EV to Sales
9.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
8.55%
ROE (Latest)
7.19%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
RSI
Bollinger Bands
KST
Dow Theory
No Trend
OBV
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend33What is working for the Company
PBT LESS OI(Q)
At Rs 35.23 cr has Grown at 129.2% (vs previous 4Q average
NET SALES(Q)
At Rs 161.76 cr has Grown at 41.9% (vs previous 4Q average
OPERATING PROFIT TO INTEREST(Q)
Highest at 8.00 times
PAT(Q)
Highest at Rs 32.38 cr.
PBDIT(Q)
Highest at Rs 49.51 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 30.61%
EPS(Q)
Highest at Rs 7.03
-1What is not working for the Company
INTEREST(Q)
Highest at Rs 6.19 cr
Loading Valuation Snapshot...
Here's what is working for Senores Pharma.
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 35.23 cr has Grown at 129.2% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 15.37 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 32.38 cr has Grown at 91.7% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 16.90 CrMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
Highest at Rs 161.76 cr and Grown
each quarter in the last five quartersMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Net Sales - Quarterly
At Rs 161.76 cr has Grown at 41.9% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 113.96 CrMOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 8.00 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Profit After Tax (PAT) - Quarterly
Highest at Rs 32.38 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 49.51 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 30.61%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 35.23 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 7.03
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Senores Pharma.
Interest - Quarterly
Highest at Rs 6.19 cr
in the last five quarters and Increased by 22.82 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
